Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) Meeting Abstract
| Authors: | Davids, M. S.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Pagel, J. M.; Wierda, W. G.; Anderson, M. A.; Darden, D. E.; Nolan, C. E.; Gressick, L. A.; Yang, J.; Chyla, B. J.; Busman, T. A.; Graham, A. M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.; Roberts, A. W. |
| Abstract Title: | Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419602616 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.8520 |
| Notes: | Meeting Abstract: 8520 -- Source: Wos |
